Stamp of approval
SAMR APPROVES CHINA LABEL IMF
Need To Know
- As largely expected, the SAMR has approved Synlait Milk for the re-registration of its China Label infant milk formula product
- The approval significantly de-risks the outlook and growth in China
- Whilst the market was largely expecting this and we don’t anticipate earnings upgrades, the actual news should improve sentiment
China’s State Administration for Market Regulation (SAMR) has approved Synlait Milk to produce A2M’s China Label infant milk formula in-line with China’s new GB standards until September 2027. Production is expected to commence later this month, with the product transitioning through 1H24. China is clearly a key market for A2M’s strategy, and the official stamp of approval should lift market sentiment.
Investment View
We believe that the downgrade cycle for A2M is largely complete, with market share gains in China likely to provide strong tailwinds for growth and margins should improve as cost headwinds subside and from cycling inventory write-downs and a more targeted marketing spend, delivering higher returns on capital. Net cash of NZ$707m on the balance sheet equates to~A$0.88-0.90 of the valuation. We retain our Buy recommendation.
Stock Overview
Share Price
Company Overview
The A2 Milk Company is a dairy nutritional company with products and trading activities in New Zealand, Australia, Greater China, North America, and a selection of emerging markets.
Disclaimers and Disclosures
Issuer
The information and opinions contained within Sandstone Insights Research were prepared by MST Financial Services Pty Ltd (ABN 54 617 475 180, AFSL 500557) ("MST").
Reliance
Whilst MST make every effort to use reliable, comprehensive information in the construction of its reports, MST make no representation, warranty or undertaking of the accuracy, timeliness or completeness of information in this report. Save for any statutory liability that cannot be excluded, MST and MST employees, representative and agents shall not be liable (whether in negligence or otherwise) for any error or inaccuracy in, or omission from, this advice or any resulting loss suffered by the recipient or any other person.
General Advice
Any advice contained within Sandstone Insights Research is general advice only and has been prepared without taking into account any person’s objectives, financial situation or needs. Any person, before acting on any advice contained within Sandstone Insights Research, should first consider consulting with a financial adviser to assess whether that advice is appropriate for their objectives, financial situation and needs.
General Disclosures
This report should be read in conjunction with MST Disclaimers and Disclosures and is published in accordance with MST Conflict Management Policy which are available on the MST website: https://www.sandstoneinsights.com.au.
Currency of Research
The recommendations made in a Sandstone Insights Research report are current as of the publication date. If you are reading a report materially after publication, it is likely that circumstances will have changed and at least some aspects of the analysis may no longer hold.
Access and Use
Any access to or use of Sandstone Insights Research is subject to the Terms of Use. By accessing or using Sandstone Insights Research you hereby agree to be bound by our Terms and Conditions and hereby liable for any monies due in payment of accessing this service. In addition you consent to us collecting and using your personal data (including cookies) in accordance with MST Privacy Policy, including for the purpose of a) setting your preferences and b) collecting readership data so MST may deliver an improved and personalised service to you. If you do not agree to MST Terms of Use and/or if you do not wish to consent to MST use of your personal data, please do not access this service.
Equities Research Methodology
Please click here for information about MST equities research methodology.